Immunoreactive peptide maps of SARS-CoV-2 and other human coronaviruses
This article has been Reviewed by the following groups
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
- Evaluated articles (ScreenIT)
Abstract
Serodiagnosis of SARS-CoV-2 infection is impeded by immunological cross-reactivity to the human coronaviruses (HCoV) SARS-CoV-2, SARS-CoV-1, MERS-CoV, OC43, 229E, HKU1, and NL63. Here we report the identification of humoral immune responses to SARS-CoV-2 and other HCoV peptides that can be used to detect asymptomatic, mild and, severe SARS-CoV-2 infections, and may enable the discovery of biomarkers for immunity following infection or vaccination.
Article activity feed
-
SciScore for 10.1101/2020.08.13.249953: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Samples & experimental design: The study was approved by the Medical Ethical Committee of Sun Yat-Sen University (approval number 2020-060).
Consent: An informed and written consent was obtained by patients.Randomization 1000 randomly selected 12 aa long scrambled peptides were added for background correction and nonspecific binding of peptides. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources To enable differential detection of antibodies specific for SARS-CoV-2 infections, we created a database comprising the proteomes of seven human coronaviruses: SARS-CoV-2, SARS, MERS, … SciScore for 10.1101/2020.08.13.249953: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: Samples & experimental design: The study was approved by the Medical Ethical Committee of Sun Yat-Sen University (approval number 2020-060).
Consent: An informed and written consent was obtained by patients.Randomization 1000 randomly selected 12 aa long scrambled peptides were added for background correction and nonspecific binding of peptides. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
Antibodies Sentences Resources To enable differential detection of antibodies specific for SARS-CoV-2 infections, we created a database comprising the proteomes of seven human coronaviruses: SARS-CoV-2, SARS, MERS, NL-63, OC-43, 229E and HKU1 (Supplementary Table 1). HKU1suggested: NoneSecondary antibodies IgG (cat no. 109-605-098, Alexa Fluor 647-AffiniPure Goat Anti-Human IgG, Fcy fragment specific, Jackson ImmunoResearch Labs) and IgM (cat no. 109-165-129, Cy™3 Anti-Human IgGsuggested: NoneIgMsuggested: NoneSoftware and Algorithms Sentences Resources The normalization, background correction and statistical comparison of peptide microarray intensities between groups was performed using the edgeR package17. edgeRsuggested: (edgeR, RRID:SCR_012802)The code for reassembly and plots was prepared using Rstudio v 1.2.501919. Rstudiosuggested: (RStudio, RRID:SCR_000432)The Heatmap plots were generated using ggplot2 package20. ggplot2suggested: (ggplot2, RRID:SCR_014601)Alignment of reactive epitopes on SARS-CoV-2 proteome was performed using Geneious version 10.0.9. Geneioussuggested: (Geneious, RRID:SCR_010519)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
